Medicenna Therapeutics Corp
TSX:MDNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medicenna Therapeutics Corp
Income from Continuing Operations
Medicenna Therapeutics Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medicenna Therapeutics Corp
TSX:MDNA
|
Income from Continuing Operations
-CA$13m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-52%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Income from Continuing Operations
-CA$12.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-91%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Income from Continuing Operations
$287.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Income from Continuing Operations
-$345.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-36%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Income from Continuing Operations
-CA$38.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Income from Continuing Operations
-$117.3m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Medicenna Therapeutics Corp
Glance View
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.
See Also
What is Medicenna Therapeutics Corp's Income from Continuing Operations?
Income from Continuing Operations
-13m
CAD
Based on the financial report for Dec 31, 2025, Medicenna Therapeutics Corp's Income from Continuing Operations amounts to -13m CAD.
What is Medicenna Therapeutics Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-52%
Over the last year, the Income from Continuing Operations growth was 52%. The average annual Income from Continuing Operations growth rates for Medicenna Therapeutics Corp have been -11% over the past three years , 2% over the past five years , and -52% over the past ten years .
